Physician profile
Lander A Smith
NPI 1861479966
$16,395.00
in general payments reported to CMS, 2019-2025
62 companies · $1,948 in 2025
The $1,948 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,375 · 2020: $2,011 · 2021: $3,075 · 2022: $2,532 · 2023: $2,157 · 2024: $2,298 · 2025: $1,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,401.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,868.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,455.17 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,106.33 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $932.01 | 2022-2025 | Rexulti |
| Pfizer INC. | $857.89 | 2019-2025 | |
| Lilly USA, LLC | $853.89 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $691.86 | 2019-2025 | Freestyle Libre, Freestyle Libre 3 |
| Abbvie INC. | $642.55 | 2020-2025 | Qulipta, Viberzi, Linzess |
| Amarin Pharma, INC. | $630.13 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $622.41 | 2019-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $573.52 | 2021-2025 | |
| Astellas Pharma US INC | $571.21 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $471.23 | 2019-2023 | Repatha, Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $456.63 | 2019-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.67 | 2019-2025 | Xifaxan, Trulance, Relistor |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $289.86 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $238.34 | 2022 | |
| Phathom Pharmaceuticals, INC. | $232.24 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $223.69 | 2021 | |
| Corium, LLC | $212.81 | 2022-2023 | Azstarys |
| Esperion Therapeutics, INC. | $206.98 | 2020-2023 | Nexletol |
| Merck Sharp & Dohme LLC | $197.04 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $183.26 | 2019-2021 | Tlando, Xyosted |
| Antares Pharma, INC. | $169.61 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Takeda Pharmaceuticals U.S.A., INC. | $165.33 | 2020-2025 | Trintellix |
| Allergan, INC. | $164.01 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $157.40 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $152.86 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $129.48 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $123.63 | 2019-2025 | Zoryve |
| Tris Pharma INC | $109.49 | 2023-2025 | Dyanavel Xr |
| Exact Sciences Corporation | $105.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $104.37 | 2024-2025 | |
| Horizon Therapeutics Plc | $91.13 | 2019-2022 | |
| Boston Scientific Corporation | $85.03 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Corcept Therapeutics | $77.72 | 2025 | Korlym |
| Lundbeck LLC | $77.50 | 2024-2025 | Rexulti, Vyepti |
| Radius Health, INC. | $76.14 | 2020-2021 | |
| Almatica Pharma LLC | $71.88 | 2024-2025 | Loreev Xr |
| Genentech USA, INC. | $66.08 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $62.09 | 2022-2024 | Givlaari |
| Dexcom, INC. | $55.75 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.12 | 2024-2025 | Caplyta |
| Eisai INC. | $43.70 | 2020-2025 | |
| Nestle Healthcare Nutrition INC. | $42.79 | 2020-2021 | |
| Halozyme INC | $35.19 | 2023 | |
| Collegium Pharmaceutical, INC. | $34.52 | 2025 | Jornay Pm |
| Mylan Specialty L.P. | $30.11 | 2019-2024 | Yupelri |
| Noven Therapeutics, LLC | $29.44 | 2024 | Xelstrym, Secuado |
| Shire North American Group INC | $25.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.99 | 2019-2021 | |
| Insulet Corporation | $18.77 | 2021 | |
| Agios Pharmaceuticals, INC. | $17.83 | 2024 | |
| Arbor Pharmaceuticals, INC. | $17.40 | 2021 | |
| Bausch Health US, LLC | $16.98 | 2021 | |
| Ironshore Pharmaceuticals INC. | $16.21 | 2019 | |
| Baxter Healthcare | $16.08 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Sumitomo Pharma America, INC. | $14.95 | 2025 | Gemtesa |
| Globus Medical, INC. | $14.81 | 2025 | Senza |
| Ironwood Pharmaceuticals, INC | $13.90 | 2020 | |
| Nevro Corp. | $12.16 | 2022 | |
| Valeritas, INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lander Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.